ALS Association Comments on Draft Payer Policies that Refuse to Cover Qalsody

Insurance form

The ALS Association sent formal responses to Blue Cross Blue Shield of Illinois, New Mexico, Texas, Oklahoma, and Montana challenging their draft policies regarding coverage of Qalsody, approved by the FDA earlier this year for treatment of people living with ALS caused by the SOD1 gene mutation. These payers are all owned by the Health Care Service Corporation.

The draft policies consider the use of Qalsody “not medically necessary.” This is unacceptable as it has both biological and clinical benefit.

In letters also shared with the Centers for Medicare and Medicaid Services and the Veterans Administration, we called on these insurers to revise their policies to:

  • Provide immediate coverage for Qalsody that is consistent with the FDA-approved indication and labeling, including in combination where appropriate.
  • Avoid unnecessary delays in access to Qalsody caused by prior authorization, tiered/fail first/step therapy, or other deliberate and unnecessary barriers to access.

You can read the full letter here.


Submitted by: Nino K. on Fri, 09/01/2023

I was diagnosed with ALS on July 2023. I would like to know more about this drug!

Submitted by: Keith R. on Mon, 09/04/2023

We all need to help get this treatment approved.

Join the conversation. Please comment below.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.